Press Releases

Oct 30, 2017
LONDON and CARLSBAD, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S.
Sep 05, 2017
- Morgan Stanley 15 th Annual Global Healthcare Conference on 13 September -             - Leerink Partners Rare Disease & Immuno-Oncology Roundtable Series on 27 September - LONDON, Sept. 05, 2017 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) ("GW" or "the Company"), a biopharmaceutical
May 24, 2017
— Pharmaceutical formulation of cannabidiol significantly reduced convulsive seizure frequency in children on multiple anti-epileptic drugs with poor seizure control — — First well-controlled clinical study of cannabidiol in Dravet syndrome, a rare, severe type of epilepsy with no FDA-approved